The city of Birmingham, Alabama, currently has 18 active clinical trials seeking participants for Diabetes research studies.
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Recruiting
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama
Conditions: Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Recruiting
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Research Site, Birmingham, Alabama
Conditions: Endocrinology, Diabetes, Type II, Obesity
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
Recruiting
The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Accel Research Site - Birmingham Clinical Research Unit, Birmingham, Alabama
Conditions: Type 2 Diabetes Mellitus (T2DM)
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
Recruiting
The goal of the DISCOVERY study is to provide innovative critical information regarding the unique natural history of glycemic control, insulin sensitivity, and β-cell function, and their mechanistic determinates, in obese adolescents at risk for developing type 2 diabetes.
Gender:
ALL
Ages:
Between 9 years and 14 years
Trial Updated:
03/10/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Diabetes Mellitus Type 2, Childhood-Onset
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
Recruiting
One in three American adults have prediabetes, and up to 70% of adults with prediabetes eventually develop type 2 diabetes. With the high cost of treating diabetes, cost-effective approaches are needed to reduce the incidence of diabetes. One new strategy may be to change when people eat. Studies in rodents suggest that a form of intermittent fasting that limits eating to a short time period each day and involves fasting for the rest of the day (time-restricted eating; TRE) improves blood sugar... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
03/05/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: PreDiabetes
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Recruiting
This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
03/03/2025
Locations: University of Alabama, Birmingham, Alabama +1 locations
Conditions: Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes
Using Early Time Restricted Feeding and Timed Light Therapy to Improve Glycemic Control in Adults With Type 2 Diabetes
Recruiting
The purpose of this study is to test whether eating earlier in the day and/or timed light therapy can improve blood sugar in people with type 2 diabetes. This study will also test whether these treatments improve other aspects of health, including the circadian (biological) clock, sleep, weight, body composition, cardiovascular health, quality of life, and mood.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
01/05/2025
Locations: University of Alabama at Birmingham; Birmingham Veterans Affairs Medical Center, Birmingham, Alabama
Conditions: Diabetes Mellitus, Type 2, Time Restricted Feeding, Light; Therapy, Complications
Denosumab for Type 1 Diabetes
Recruiting
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
12/03/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Type 1 Diabetes
Mindfulness-Based Diabetes Education for Adults With Elevated Diabetes Distress
Recruiting
Diabetes distress is common affecting over one-third of people with type 2 diabetes, negatively impacting self-management and outcomes, and disproportionately affecting low-income individuals. The proposed project will conduct a pilot randomized controlled trial comparing Mindfulness-Based Diabetes Education to standard Diabetes Self-Management Education in adults with type 2 diabetes and elevated diabetes distress who receive care within safety-net healthcare systems in order to assess feasibil... Read More
Gender:
ALL
Ages:
Between 19 years and 70 years
Trial Updated:
11/11/2024
Locations: Cooper Green Mercy Health Systems, Birmingham, Alabama
Conditions: Type 2 Diabetes
Weight Inclusive and Adaptive Strategies to Enhance Cardiometabolic Health in Black Adults
Recruiting
The proposed 6-month pilot Sequential Multiple Assignment Randomize Trial (SMART) has two aims. The first and primary aim is to determine the feasibility of conducting a full-scale SMART to compare weight-focused (i.e., weight loss) and weight-neutral (i.e., weight loss is not an explicit goal) adaptive biobehavioral interventions for improving cardiometabolic health in Black adults with overweight or obesity (BMI ≥27 kg/m2) plus at least one weight-related cardiometabolic condition (high blood... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Obesity, Prehypertension, Hypertension, PreDiabetes, Type 2 Diabetes, Dyslipidemia
Glycemic Control After Antenatal Corticosteroids in Women with Pregestational and Gestational Diabetes
Recruiting
There is a fundamental gap in understanding the maternal and neonatal effects of antenatal corticosteroid (ACS) administration in women with threatened preterm birth (PTB) who have diabetes. Since the initial discovery of ACS for neonatal benefit in 1972, more than 40 randomized controlled trials have been performed evaluating its efficacy. However, none of these trials have included women with T2DM, and there is limited data among women with gestational diabetes. While ACS have been shown to re... Read More
Gender:
ALL
Ages:
50 years and below
Trial Updated:
10/04/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational